CTLs recognize cancer cells through the presentation of tumor-associated antigens (TAAs) on the surface of cancer cells. These antigens are processed and presented by major histocompatibility complex (MHC) class I molecules. When a CTL’s T-cell receptor (TCR) binds to an MHC I molecule presenting a TAA, the CTL is activated to kill the target cell.
